SLC5A2 and hydrops fetalis: Given that impaired diastolic function is a crucial pathophysiological feature of HF, mainly subclinical HFpEF,—often present long before HF becomes clinical apparent—our data bolster the hypothesis that SGLT2 inhibitors could prevent the development of HF by improving left ventricular filling pressure in patients with T2D.